Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.

[1]  P. O'Malley.  Review: β blockers reduce mortality and therapy withdrawal in heart failure but increase dizziness and bradycardia , 2005, ACP journal club.

[2]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[3]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[4]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[5]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[6]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[7]  D. Baker,et al.  Management of heart failure. I. Pharmacologic treatment. , 1994, JAMA.

[8]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[9]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[10]  Lawrence Joseph,et al.  β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .

[11]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[12]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[13]  M. Gheorghiade,et al.  Practical aspects of using beta-adrenergic blockade in systolic heart failure. , 2001, The American journal of medicine.

[14]  E. Braunwald.  Heart Disease: A Textbook of Cardiovascular Medicine , 1992, Annals of Internal Medicine.

[15]  H. Sacks,et al.  Early or Deferred Zidovudine Therapy in HIV-Infected Patients without an AIDS-Defining Illness , 1995, Annals of Internal Medicine.

[16]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[17]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[18]  Eric J. Eichhorn.  Prognosis determination in heart failure. , 2001, The American journal of medicine.

[19]  L. Stevenson,et al.  Medical management of advanced heart failure. , 2002, JAMA.

[20]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[21]  W. Abraham.  Beta-blockers: the new standard of therapy for mild heart failure. , 2000, Archives of internal medicine.

[22]  E. Braunwald,et al.  Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. , 1966, The New England journal of medicine.

[23]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[24]  G Cooper,et al.  Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. , 2000, Circulation.